UB-165 je lek koji deluje kao agonist neuronskih nikotinskih acetilholinskih receptora. On je pun agonist za α3β2 i parcijalni agonist za α4β2 izoformu. Ovaj ligand se koristi za izučavanje uloge ovih podtipova receptora u oslobađanju dopamina i noradrenalina u mozgu.[1][2] On je takođe služio kao vodeće jedinjenje za razvoj brojnih drugih selektivnih liganda nikotinskih receptora.[3][4][5][6]
^Sharples, C. G.; Kaiser, P.; Soliakov; Marks; Collins; Washburn; Wright; Spencer; Gallagher (2000). „UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes”. Journal of Neuroscience. 20 (8): 2783—2791. PMID10751429.
^Gohlke, H.; Gündisch; Schwarz; Seitz; Tilotta; Wegge (2002). „Synthesis and nicotinic binding studies on enantiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo4.2.1non-2-ene UB-165”. Journal of Medicinal Chemistry. 45 (5): 1064—1072. PMID11855986. doi:10.1021/jm010936y.
^Sharples, C. G.; Karig; Simpson; Spencer; Wright; Millar; Wonnacott; Gallagher (2002). „Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (+/-)-UB-165”. Journal of Medicinal Chemistry. 45 (15): 3235—3245. PMID12109907. doi:10.1021/jm020814l.
^Sutherland, A.; Gallagher, T.; Sharples, C.; Wonnacott, S. (2003). „Synthesis of two fluoro analogues of the nicotinic acetylcholine receptor agonist UB-165”. The Journal of Organic Chemistry. 68 (6): 2475—2478. PMID12636420. doi:10.1021/jo026698b.
^Karig, G.; Large; Sharples; Sutherland; Gallagher; Wonnacott (2003). „Synthesis and nicotinic binding of novel phenyl derivatives of UB-165. Identifying factors associated with alpha7 selectivity”. Bioorganic & Medicinal Chemistry Letters. 13 (17): 2825—2828. PMID14611837. doi:10.1016/S0960-894X(03)00594-8.
